Parkinson’s Disease

Copyright © 2012 Akiko Muroyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
2. J. Jankovic and L. G. Aguilar, “Current approaches to the treatment of Parkinson's disease,” Neuropsychiatric Disease and Treatment, vol. 4, no. 4, pp. 743–757, 2008. View at Google Scholar · View at Scopus
3. J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, “Chronic parkinsonism in humans due to a product of meperidine-analog synthesis,” Science, vol. 219, no. 4587, pp. 979–980, 1983. View at Google Scholar · View at Scopus
4. R. S. Burns, C. C. Chiueh, and S. P. Markey, “A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 14, pp. 4546–4550, 1983. View at Google Scholar
5. P. Jenner, “Functional models of Parkinson's disease: a valuable tool in the development of novel therapies,” Annals of Neurology, vol. 64, no. 2, pp. S16–S29, 2008. View at Publisher · View at Google Scholar · View at Scopus
6. W. D. Parker, S. J. Boyson, and J. K. Parks, “Abnormalities of the electron transport chain in idiopathic Parkinson's disease,” Annals of Neurology, vol. 26, no. 6, pp. 719–723, 1989. View at Publisher · View at Google Scholar · View at Scopus
7. A. H. V. Schapira, J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark, and C. D. Marsden, “Mitochondrial complex I deficiency in Parkinson's disease,” Lancet, vol. 1, no. 8649, p. 1269, 1989. View at Google Scholar · View at Scopus
8. Y. Mizuno, H. Yoshino, S. I. Ikebe et al., “Mitochondrial dysfunction in Parkinson's disease,” Annals of Neurology, vol. 44, no. 3, pp. S99–S109, 1998. View at Google Scholar · View at Scopus
9. H. Saggu, J. Cooksey, D. Dexter et al., “A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra,” Journal of Neurochemistry, vol. 53, no. 3, pp. 692–697, 1989. View at Google Scholar · View at Scopus
10. J. Sian, D. T. Dexter, A. J. Lees et al., “Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia,” Annals of Neurology, vol. 36, no. 3, pp. 348–355, 1994. View at Google Scholar · View at Scopus
11. E. Hasegawa, K. Takeshige, T. Oishi, Y. Murai, and S. Minakami, “1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles,” Biochemical and Biophysical Research Communications, vol. 170, no. 3, pp. 1049–1055, 1990. View at Publisher · View at Google Scholar · View at Scopus
12. K. Sriram, K. S. Pai, M. R. Boyd, and V. Ravindranath, “Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice,” Brain Research, vol. 749, no. 1, pp. 44–52, 1997. View at Publisher · View at Google Scholar · View at Scopus
13. M. Fujita, H. Itokawa, and Y. Sashida, “Studies on the components of Magnolia obovata Thunb. III. Occurrence of magnolol and honokiol in M. obovata and other allied plants (Japanese),” Yakugaku Zasshi, vol. 93, no. 4, pp. 429–434, 1973. View at Google Scholar · View at Scopus
14. Y. Maruyama and H. Kuribara, “Overview of the pharmacological features of honokiol,” CNS Drug Reviews, vol. 6, no. 1, pp. 35–44, 2000. View at Google Scholar · View at Scopus
15. H. Kuribara, W. B. Stavinoha, and Y. Maruyama, “Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice,” Journal of Pharmacy and Pharmacology, vol. 50, no. 7, pp. 819–826, 1998. View at Google Scholar · View at Scopus
16. Q. Xu, L. T. Yi, Y. Pan et al., “Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 3, pp. 715–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
17. N. Matsui, H. Nakashima, Y. Ushio et al., “Neurotrophic effect of magnolol in the hippocampal CA1 region of Senescence-Accelerated Mice (SAMP1),” Biological and Pharmaceutical Bulletin, vol. 28, no. 9, pp. 1762–1765, 2005. View at Publisher · View at Google Scholar · View at Scopus
18. Y. R. Lin, H. H. Chen, C. H. Ko, and M. H. Chan, “Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage,” European Journal of Pharmacology, vol. 537, no. 1–3, pp. 64–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
19. C. M. Chen, S. H. Liu, and S. Y. Lin-Shiau, “Honokiol, a neuroprotectant against mouse cerebral ischaemia, mediated by preserving Na⁺, K⁺-ATPase activity and mitochondrial functions,” Basic and Clinical Pharmacology and Toxicology, vol. 101, no. 2, pp. 108–116, 2007. View at Publisher · View at Google Scholar · View at Scopus
20. N. Matsui, K. Takahashi, M. Takeichi et al., “Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice,” Brain research, vol. 1305, pp. 108–117, 2009. View at Google Scholar · View at Scopus
21. H.-H. Chen, S.-C. Lin, and M.-H. Chan, “Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism,” Neurodegenerative Diseases, vol. 8, no. 5, pp. 364–374, 2011. View at Publisher · View at Google Scholar
22. Y. Fukuyama, K. Nakade, Y. Minoshima, R. Yokoyama, H. Zhai, and Y. Mitsumoto, “Neurotrophic activity of honokiol on the cultures of fetal rat cortical neurons,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 8, pp. 1163–1166, 2002. View at Publisher · View at Google Scholar · View at Scopus
23. H. Zhai, K. Nakade, M. Oda et al., “Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2),” European Journal of Pharmacology, vol. 516, no. 2, pp. 112–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
24. H. Zhai, K. Nakade, Y. Mitsumoto, and Y. Fukuyama, “Honokiol and magnolol induce Ca²⁺ mobilization in rat cortical neurons and human neuroblastoma SH-SY5Y cells,” European Journal of Pharmacology, vol. 474, no. 2-3, pp. 199–204, 2003. View at Publisher · View at Google Scholar · View at Scopus
25. A. Mori, S. Ohashi, M. Nakai, T. Moriizumi, and Y. Mitsumoto, “Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice,” Neuroscience Research, vol. 51, no. 3, pp. 265–274, 2005. View at Publisher · View at Google Scholar · View at Scopus
26. T. Kawasaki, K. Ishihara, Y. Ago, A. Baba, and T. Matsuda, “Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 1, pp. 274–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
27. M. Hattori, Y. Endo, and S. Takebe, “Metabolism of magnolol from magnoliae cortex. II. Absorption, metabolism and excretion of [ring-¹⁴C]magnolol in rats,” Chemical and Pharmaceutical Bulletin, vol. 34, no. 1, pp. 158–167, 1986. View at Google Scholar
28. T. H. Tsai, C. J. Chou, and C. F. Chen, “Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection,” Journal of Pharmacy and Pharmacology, vol. 48, no. 1, pp. 57–59, 1996. View at Google Scholar · View at Scopus
29. J. P. O'Callaghan, D. B. Miller, and J. F. Reinhard, “Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Brain Research, vol. 521, no. 1-2, pp. 73–80, 1990. View at Publisher · View at Google Scholar · View at Scopus
30. R. Dringen, B. Pfeiffer, and B. Hamprecht, “Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione,” Journal of Neuroscience, vol. 19, no. 2, pp. 562–569, 1999. View at Google Scholar · View at Scopus
31. J. Hirrlinger, J. B. Schulz, and R. Dringen, “Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells,” Journal of Neuroscience Research, vol. 69, no. 3, pp. 318–326, 2002. View at Publisher · View at Google Scholar · View at Scopus
32. P. E. Batchelor, G. T. Liberatore, J. Y. F. Wong et al., “Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor,” Journal of Neuroscience, vol. 19, no. 5, pp. 1708–1716, 1999. View at Google Scholar · View at Scopus
33. Y. C. Lo, C. M. Teng, C. F. Chen, C. C. Chen, and C. Y. Hong, “Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation,” Biochemical Pharmacology, vol. 47, no. 3, pp. 549–553, 1994. View at Publisher · View at Google Scholar · View at Scopus
34. H. Haraguchi, H. Ishikawa, N. Shirataki, and A. Fukuda, “Antiperoxidative activity of neolignans from Magnolia obovata,” Journal of Pharmacy and Pharmacology, vol. 49, no. 2, pp. 209–212, 1997. View at Google Scholar · View at Scopus
35. J. Lee, E. Jung, J. Park et al., “Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-κB activation signaling,” Planta Medica, vol. 71, no. 4, pp. 338–343, 2005. View at Publisher · View at Google Scholar
36. L. D. Kong, C. H. K. Cheng, and R. X. Tan, “Inhibition of MAO a and B by some plant-derived alkaloids, phenols and anthraquinones,” Journal of Ethnopharmacology, vol. 91, no. 2-3, pp. 351–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
37. R. E. Heikkila, L. Manzino, F. S. Cabbat, and R. C. Duvoisin, “Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors,” Nature, vol. 311, no. 5985, pp. 467–469, 1984. View at Google Scholar · View at Scopus
38. J. A. Javitch, R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder, “Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 7, pp. 2173–2177, 1985. View at Google Scholar · View at Scopus
39. R. R. Ramsay and T. P. Singer, “Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria,” Journal of Biological Chemistry, vol. 261, no. 17, pp. 7585–7587, 1986. View at Google Scholar · View at Scopus
40. W. J. Nicklas, I. Vyas, and R. E. Heikkila, “Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine,” Life Sciences, vol. 36, no. 26, pp. 2503–2508, 1985. View at Publisher · View at Google Scholar · View at Scopus
41. P. Chan, L. E. DeLanney, I. Irwin, J. W. Langston, and D. Di Monte, “Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain,” Journal of Neurochemistry, vol. 57, no. 1, pp. 348–351, 1991. View at Google Scholar · View at Scopus
42. M. Nakai, A. Mori, A. Watanabe, and Y. Mitsumoto, “1-Methyl-4-phenylpyridinium (MPP⁺) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential ($\mathrm{\Delta }{\mathrm{\Psi }}_{\text{m}}$) in rat striatum,” Experimental Neurology, vol. 179, no. 1, pp. 103–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
43. Y. Zhang, O. Marcillat, C. Giulivi, L. Ernster, and K. J. A. Davies, “The oxidative inactivation of mitochondrial electron transport chain components and ATPase,” Journal of Biological Chemistry, vol. 265, no. 27, pp. 16330–16336, 1990. View at Google Scholar · View at Scopus
44. S. Przedborski, M. Levivier, H. Jiang et al., “Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine,” Neuroscience, vol. 67, no. 3, pp. 631–647, 1995. View at Publisher · View at Google Scholar · View at Scopus
45. W. A. Holtz, J. M. Turetzky, Y. J. I. Jong, and K. L. O'Malley, “Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics,” Journal of Neurochemistry, vol. 99, no. 1, pp. 54–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
46. G. Cohen and R. E. Heikkila, “The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6 hydroxydopamine, dialuric acid, and related cytotoxic agents,” Journal of Biological Chemistry, vol. 249, no. 8, pp. 2447–2452, 1974. View at Google Scholar · View at Scopus
47. R. Kumar, A. K. Agarwal, and P. K. Seth, “Free radical-generated neurotoxicity of 6-hydroxydopamine,” Journal of Neurochemistry, vol. 64, no. 4, pp. 1703–1707, 1995. View at Google Scholar · View at Scopus
48. H. Dudek, S. R. Datta, T. F. Franke et al., “Regulation of neuronal survival by the serine-threonine protein kinase Akt,” Science, vol. 275, no. 5300, pp. 661–665, 1997. View at Publisher · View at Google Scholar · View at Scopus
49. C. Malagelada, H. J. Zong, and L. A. Greene, “RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation,” Journal of Neuroscience, vol. 28, no. 53, pp. 14363–14371, 2008. View at Publisher · View at Google Scholar · View at Scopus
50. H. Aleyasin, M. W. C. Rousseaux, P. C. Marcogliese et al., “DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 7, pp. 3186–3191, 2010. View at Publisher · View at Google Scholar · View at Scopus